ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

ponesimod

Also written as “Ponesimod”, “ACT-128800” and “Ponesimod 10 mg”.

Its studies are mostly in Multiple Sclerosis · Psoriasis · Colitis, Ulcerative · Bronchiolitis Obliterans Syndrome, led by 2 companies.

Drug pagePonesimod: every studyAll 16 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Apr 21, 201516 company-led studies, 2 open or runningNext primary completion: Aug 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnson140 open or runningphase 3since Apr 21, 2015Feb 26, 2009none ahead
Vanda Pharmaceuticalsits history only22 open or runningphase 3since Jan 20, 2026Jan 20, 2026Aug 2028phase 3 · NCT07362017

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Johnson & Johnson only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 26, 2009First study: phase 2 study in Plaque PsoriasisFirst studyNCT00852670 · 66 enrolled · Austria, France, Germany and more
  2. Oct 30, 2009Phase 2 study in Multiple SclerosisNCT01006265 · 464 enrolled · United States, Australia, Austria and more
  3. Mar 24, 2010Phase 2 study in Multiple SclerosisNCT01093326 · 353 enrolled · United States, Austria, Bulgaria and more
  4. Sep 22, 2010Phase 2 study in PsoriasisNCT01208090 · 326 enrolled · Austria, Belgium, Bulgaria and more
  5. Jan 6, 2014Phase 1 study in Safety and TolerabilityNCT02029482 · 16 enrolled · United Kingdom
  6. Feb 19, 2014Phase 1 study in HealthyNCT02068235 · 17 enrolled · United Kingdom
  7. Apr 29, 2014Phase 1 study in PharmacokineticsNCT02126956 · 6 enrolled · Switzerland
  8. May 9, 2014Phase 1 study in HealthyNCT02136888 · 116 enrolled · United States
  9. Aug 21, 2014Phase 1 study in HealthyNCT02223832 · 20 enrolled · United States
  10. Apr 21, 2015Phase 3 study in Multiple SclerosisNCT02425644 · 1,133 enrolled · United States, Belarus, Bosnia and Herzegovina and more
  11. Apr 28, 2015Phase 2 study in Bronchiolitis Obliterans SyndromeNCT02461134 · 1 enrolled
  12. Aug 25, 2016Phase 3 study in Multiple SclerosisNCT02907177 · 136 enrolled · United States, Australia, Austria and more
  13. Jul 20, 2017Phase 3 study in Multiple SclerosisNCT03232073 · 877 enrolled · United States, Belarus, Bosnia and Herzegovina and more
  14. Sep 21, 2022Phase 1 study in HealthyNCT05552196 · 28 enrolled · Belgium

TargetBeta

S1PR1 →read by rule
“An orally available sphingosine-1-phosphate receptor 1 (S1PR1, S1P1) agonist that acts as a functional antagonist, ”NCIt, by rule
“Sphingosine 1-phosphate receptor Edg-1 agonist”ChEMBL 37, by rule

Other programs on S1PR1

ProgramCompanyFurthest phaseStudies
fingolimodruleNovartisphase 455
etrasimodrulePfizerphase 321
cenerimodruleViatrisphase 314
mocravimodruleNovartisphase 35

Studies

All 14 Johnson & Johnson leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05552196Healthy · Belgium1CompletedMar 5, 202328
NCT03232073Multiple Sclerosis · United States, Belarus, Bosnia and Herzegovina and more3CompletedJan 16, 2024877
NCT02907177Multiple Sclerosis · United States, Australia, Austria and more3TerminatedMar 26, 2020136
NCT02461134Bronchiolitis Obliterans Syndrome2TerminatedMar 2, 20171
NCT02425644Multiple Sclerosis · United States, Belarus, Bosnia and Herzegovina and more3CompletedMay 16, 20191,133
NCT02223832Healthy · United States1CompletedApr 200920
NCT02136888Healthy · United States1CompletedFeb 2012116
NCT02126956Pharmacokinetics · Switzerland1CompletedApr 20096
NCT02068235Healthy · United Kingdom1CompletedNov 201417
NCT02029482Safety and Tolerability · United Kingdom1CompletedJun 201016
NCT01208090Psoriasis · Austria, Belgium, Bulgaria and more2CompletedOct 31, 2012326
NCT01093326Multiple Sclerosis · United States, Austria, Bulgaria and more2CompletedSep 6, 2023353
NCT01006265Multiple Sclerosis · United States, Australia, Austria and more2CompletedJun 1, 2011464
NCT00852670Plaque Psoriasis · Austria, France, Germany and more2CompletedJul 200966

How it is read

Names in the registry

  • “Ponesimod”, 6 entries
  • “ACT-128800”, 5 entries
  • “Ponesimod 10 mg”, 2 entries
  • “Ponesimod 20 mg”, 2 entries
  • “Ponesimod 40 mg”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.